Lee Jae Min, Shim Ye Jee, Kim Do-Hoon, Jung Nani, Ha Jung-Sook
Department of Pediatrics, Yeungnam University College of Medicine, Daegu 42415, Korea.
Department of Pediatrics, Keimyung University School of Medicine, Daegu 42601, Korea.
Children (Basel). 2021 Mar 15;8(3):224. doi: 10.3390/children8030224.
Mercaptopurine (MP) is a commonly used maintenance regimen for childhood acute lymphoblastic leukemia (ALL). However, 6-MP has a narrow therapeutic index, which causes dose-limiting toxicities in hematopoietic tissues. Recent studies reported several candidate pharmacogenetic markers such as TPMT, NUDT15, ITPA, and APEX1, which predict the possibility of 6-MP related toxicities. The aim of this study is to evaluate the effect of major variants of these genes on 6-MP intolerances and toxicities in pediatric acute lymphoblastic leukemia (ALL) patients. A total of 83 pediatric ALL patients were included (56 males and 27 females). The NUDT15 c.415C>T (rs116855232), NUDT15 c.55_56insGAGTCG (rs746071566), ITPA c.94C>A (rs1127354), ITPA c.IVS2+21A>C (rs7270101), APEX c.190A>G (rs2307486), and TPMT variants were analyzed by sanger sequencing. Correlations between indexes of 6-MP-related toxicities or 6-MP intolerance (absolute neutrophil count [ANC] at several time point, days of ANC < 1 × 10/mm, days of ANC < 0.5 × 10/mm, frequency of febrile neutropenia, maximum AST and ALT, 6-MP dose and 6-MP dose intensity during maintenance therapy) and genetic variations were analyzed. The NUDT15 c.415C>T allele carrier showed significantly low 6-MP doses at the final maintenance therapy period than the wild type carrier ( = 0.007). The 6-MP dose intensities at the sixth and final maintenance period were also significantly low in NUDT15 c.415C>T carriers ( = 0.003 and 0.008, respectively). However, indexes for neutropenia, days of febrile neutropenia, maximum AST, and ALT levels were not associated with the presence of c.415C>T as well as other analyzed variants. When analyzing the effect of the coexistence of NUDT15 c.415C>T and ITPA c.94C>A, no significant differences were found between the NUDT15 c.415C>T carrier and carrier with both variations. The NUDT15 c.415C>T was the most useful marker to predict 6-MP intolerance among analyzed variants in our study population. Although we could not find association of those variants with 6-MP induced toxicities and the synergistic effects of those variants, a well-planed larger scale study would be helpful in clarifying new candidates and their clinical effects.
巯嘌呤(MP)是儿童急性淋巴细胞白血病(ALL)常用的维持治疗方案。然而,6-巯基嘌呤(6-MP)的治疗指数较窄,会在造血组织中引起剂量限制性毒性。最近的研究报道了几种候选药物遗传学标志物,如硫嘌呤甲基转移酶(TPMT)、NUDT15、次黄嘌呤-鸟嘌呤磷酸核糖转移酶(ITPA)和脱嘌呤/脱嘧啶核酸内切酶1(APEX1),这些标志物可预测6-MP相关毒性的可能性。本研究的目的是评估这些基因的主要变异对小儿急性淋巴细胞白血病(ALL)患者6-MP不耐受性和毒性的影响。共纳入83例小儿ALL患者(56例男性和27例女性)。通过桑格测序分析NUDT15基因c.415C>T(rs116855232)、NUDT15基因c.55_56insGAGTCG(rs746071566)、ITPA基因c.94C>A(rs1127354)、ITPA基因c.IVS2+21A>C(rs7270101)、APEX基因c.190A>G(rs2307486)以及TPMT基因变异。分析6-MP相关毒性或6-MP不耐受指标(几个时间点的绝对中性粒细胞计数[ANC]、ANC<1×10⁹/L的天数、ANC<0.5×10⁹/L的天数、发热性中性粒细胞减少的频率、最高谷草转氨酶和谷丙转氨酶、维持治疗期间的6-MP剂量和6-MP剂量强度)与基因变异之间的相关性。NUDT15基因c.415C>T等位基因携带者在最终维持治疗期的6-MP剂量显著低于野生型携带者(P=0.007)。NUDT15基因c.415C>T携带者在第六次和最终维持期的6-MP剂量强度也显著较低(分别为P=0.003和0.008)。然而,中性粒细胞减少指标、发热性中性粒细胞减少天数、最高谷草转氨酶和谷丙转氨酶水平与c.415C>T以及其他分析的变异的存在无关。在分析NUDT15基因c.415C>T和ITPA基因c.94C>A共存的影响时,NUDT15基因c.415C>T携带者与两种变异均有的携带者之间未发现显著差异。在我们的研究人群中,NUDT15基因c.415C>T是预测6-MP不耐受最有用的标志物。虽然我们未发现这些变异与6-MP诱导的毒性以及这些变异的协同效应之间的关联,但一项精心设计的更大规模研究将有助于明确新的候选标志物及其临床效应。